Bernard J. Zovighian - 07 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TMTT
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
07 May 2022
Net transactions value
-$750,884
Form type
4
Filing time
10 May 2022, 21:05:04 UTC
Previous filing
04 May 2022
Next filing
17 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability $63,629 -633 -1.5% $100.52 40,573 07 May 2022 Direct
transaction EW Common Stock Options Exercise $0 +12,600 +31% $0.000000 53,173 08 May 2022 Direct F1
transaction EW Common Stock Tax liability $687,255 -6,837 -13% $100.52 46,336 08 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -12,600 -100% $0.000000* 0 08 May 2022 Common Stock 12,600 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.